|
Slide decks of the oral presentations given at the EBF DBS workshop in Brussels can be viewed and downloaded from the slides page |
 |
EBF Workshop
Connecting Strategies on
Dried Blood Spots
June 17-18 • 2010 • Sheraton Hotel Brussels
Brussels • Belgium
The Workshop will open on Thursday, June 17, 2010, at 08:30
and it closes on Friday, June 18, 2010, at 14:30. |
 |
The intention of this Workshop is to bring together experts from all stakeholders involved in this DBS technique (Bioanalysis, Toxicology, Pharmacokinetics, Central Labs, Quality Assurance, Regulatory Authorities, CROs and Instrument Vendors) to connect and discuss the potential application and further growth of DBS in drug development. All participants are invited to present their views and suggestions, based on own experience, during the discussion.
The Dried Blood Spot (DBS) technique is getting a lot of attention and its advantages are now recognized in the bioanalytical, clinical and non clinical community. In preclinical drug development, DBS offers ethical benefits with regards to the ‘3Rs’ guiding principles: the reduced blood volume needed for DBS enables serial blood sampling from one animal rather than bleeds from several animals which significantly reduces the number of animals and improves the quality of the data for pharmacokinetic and toxicokinetic preclinical studies. Considering clinical applications, DBS offers the advantage of less invasive sampling like finger prick rather than by venous cannulation and the lower blood volume required is a great advantage in paediatrics too. Finally, DBS offers logistical and cost benefits including ease of sample handling, storage and shipment of the DBS cards at room temperature.
The Workshop is organised as an open discussion forum to meet the requirements and expectations of professionals from the generic and the research based industry, CROs, instrument vendors, academia and regulatory agencies. Department heads, project managers, bioanalytical scientists and consultants in R&D, in regulatory affairs, quality assurance, pharmacokinetics and clinical studies and so forth should attend in order to contribute with their experience. All delegates are invited to contribute actively to the scientific discussions across the disciplines.
| 
